Finance

Themis preps first clinical test of oncolytic viral approach with €40M round

As Themis continues to develop vaccines using its measles viral vectors to treat infectious diseases, the Austrian biotech also hopes to use its new €40 million ($44.3 million) series D round to conduct its first...

Bayer invests $20M in One Drop's digital platform

As digital health's footprint continues to grow, Bayer is leading One Drop's $40 million series B round and licensing its diabetes self-management platform for use in other disease areas. Bayer AG (Xetra:BAYN) said Tuesday it...

Sept. 16 Financial Quick Takes: Karyopharm, Mission Bay, Autolus, BenevolentAI, Edigene

Karyopharm in $150M royalty deal  Karyopharm Therapeutics Inc. (NASDAQ:KPTI) entered into a royalty deal with HealthCare Royalty Partners under which it could receive up to $150 million tied to multiple myeloma drug Xpovio selinexor. Karyopharm...

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...

Sept. 13 Financial Quick Takes: Satsuma prices IPO; plus Catalyst scuttles fund-raising and Imara plans a listing

Satsuma raises $82.5M in NASDAQ listing  Migraine company Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) gained $1.90 (13%) to $16.90 after raising $82.5 million in a bumped-up IPO. The company sold 5.5 million shares, upsized from the proposed...

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

With GSK effectively bowing out of a 2013 build-to-buy deal with Avalon Ventures after delivering just one exit, the VC is seeking to navigate a future for a handful of Phase I-ready programs it created...

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

Big gain for 10x after upsized IPO prices above range  Single-cell analytics company 10x Genomics Inc. (NASDAQ:TXG) gained $13.75 (35%) to $52.75 in its first day of trading after raising $390 million in its IPO....

Inotrem raises €39M series B for septic shock therapy, diagnostic

A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech to get its lead program for septic shock through Phase IIb testing. Morningside Ventures led the round, with participation...

Genenta’s series C marks start of Qianzhan’s European push

In the latest show of support for European biotech by Chinese investors, Genenta raised €13.2 million in a series C round that marks the first investment in the region by Shanghai’s Qianzhan Investment Management. Qianzhan...

With $22M B round, OncoCell to launch prostate cancer test

With its $22.2 million series B round, OncoCell plans to launch next summer the first blood test from its diagnostic platform based on immune gene expression profiles. Mark McDonough, president and CEO of OncoCell Mdx...

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

Qiming leads Insilico’s $37M B round  Insilico Medicine Inc. (Hong Kong, China) raised $37 million in a series B round led by Qiming Venture Partners. Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu...

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

BioNTech’s IPO filing revealed that it has not yet received $100 million from a Hong Kong-based investor who was part of its recent $325 million series B round, likely because of “disruptions” in Hong Kong...

Pharvaris raises $66M series B for clinical development of oral HAE therapy

Pharvaris will use its new $66 million series B round to fund early clinical development of its lead compound, an oral small molecule that could give HAE patients an easier-to-use option than existing injectable therapies...

Trucode: advancing nuclease-free, viral vector-independent gene therapy

After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode. This time around, the technology is more advanced and...

4Bio hopes to mix and match next-gen therapies with $150M fund

4Bio Capital is aiming to invest solely in new modalities and treatment paradigms with its new venture fund, including in start-ups that combine more than one novel approach. The firm has raised $50 million in...